.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,225,303

« Back to Dashboard

Details for Patent: 6,225,303

Title: Use of green porphyrins to treat neovasculature in the eye
Abstract:Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.
Inventor(s): Miller; Joan W. (Boston, MA), Gragoudas; Evangelos S. (Boston, MA)
Assignee: Massachusetts Eye and Ear Infirmary (Boston, MA)
Filing Date:Jul 06, 1999
Application Number:09/347,382
Claims:1. A method of treating unwanted choroidal neovasculature in a shortened treatment time, the method comprising the steps of:

administering to a primate subject in need of such treatment an amount of a porphyrin dye sufficient to permit an effective amount to localize in the neovasculature; and

irradiating the neovasculature with light from a laser having an irradiance in the range from at least about 300 mW/cm.sup.2 to about 900 mW/cm.sup.2, the light being absorbed by the porphyrin dye so as to occlude the neovasculature.

2. The method of claim 1, wherein the porphyrin is green porphyrin.

3. The method of claim 1, wherein the porphyrin is complexed with low-density lipoprotein.

4. The method of claim 1, wherein the porphyrin is contained in a liposomal preparation.

5. The method of claim 1, wherein the irradiance is about 600 mW/cm.sup.2.

6. The method of claim 1, wherein the light has a fluence in the range of from about 50 Joules/cm.sup.2 to about 200 Joules/cm.sup.2.

7. The method of claim 5, wherein the light has a fluence in the range of from about 50 Joules/cm.sup.2 to about 200 Joules/cm.sup.2.

8. The method of claim 1, wherein the primate subject has age-related macular degeneration and occlusion of the neovasculature ameliorates symptoms of the age-related macular degeneration.

9. A method of treating age-related macular degeneration in a primate subject having unwanted choroidal neovasculature in a shortened treament time, the method comprising the steps of:

administering to the primate subject an amount of a green porphyrin dye sufficient to permit an effective amount to localize in the neovasculature; and

irradiating the neovasculature with light from a laser having an irradiance in the range from at least about 300 mW/cm.sup.2 to about 900 mW/cm.sup.2, the light being absorbed by the porphyrin dye so as to occlude the neovasculature.

10. The method of claim 9, wherein the porphyrin is complexed with low-density lipoprotein.

11. The method of claim 9, wherein the porphyrin is contained in a liposomal preparation.

12. The method of claim 9, wherein the irradiance is about 600 mW/cm.sup.2.

13. The method of claim 9, wherein the light has a fluence in the range of from about 50 Joules/cm.sup.2 to about 200 Joules/cm.sup.2.

14. The method of claim 12, wherein the light has a fluence in the range of from about 50 Joules/cm.sup.2 to about 200 Joules/cm.sup.2.

15. The method of claim 5, wherein the light has afluence of 50 Joules/cm.sup.2.

16. The method of claim 12, wherein the light has a fluence of 50 Joules/cm.sup.2.

17. The method of claim 2, wherein the light has a wavelength in the range of 550 to 695 nm.

18. The method of claim 5, wherein the light has a wavelength in the range of 550 to 695 nm.

19. The method of claim 12, wherein the light has a wavelength in the range of 550 to 695 nm.

20. The method of claim 1, wherein the primate subject has a disorder selected from the group consisting of age related macular degeneration, ocular histoplasmosis syndrome and myopia, wherein occlusion of the neovasculature ameliorates the disorder.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc